Skip to main content
SpringerLink
Log in

Viloxazine for attention-deficit hyperactivity disorder: a new formulation for a new indication

  • Therapy in Practice
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

Abstract

Viloxazine (SPN-812), an age-old antidepressant, has recently been approved by the US FDA for the treatment of attention-deficit hyperactivity disorder (ADHD) in children aged 6–17 years, at a dose range of 100–400 mg/day. Viloxazine acts primarily by norepinephrine reuptake inhibition and may also modulate the serotonergic system. The efficacy of viloxazine for the treatment of ADHD in children aged 6–17 years has been demonstrated in a series of short-term clinical trials. The most common adverse events include somnolence and gastrointestinal upset, while the FDA has issued a black-box warning regarding suicidal ideation or behavior. This article summarizes the information regarding viloxazine based on previously published narrative reviews, preclinical studies, and blinded controlled clinical trials.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Substance Abuse and Mental Health Services Administration. DSM-5 changes: implications for child serious emotional disturbance. Rockville: Substance Abuse and Mental Health Services Administration (US); 2016.

    Google Scholar 

  2. Caye A, Swanson JM, Coghill D, et al. Treatment strategies for ADHD: an evidence-based guide to select optimal treatment. Mol Psychiatry. 2019;24(3):390–408.

    Article  CAS  Google Scholar 

  3. Cortese S. Pharmacologic treatment of attention deficit-hyperactivity disorder. N Engl J Med. 2020;383(11):1050–6.

    Article  CAS  Google Scholar 

  4. Budur K, Mathews M, Adetunji B, et al. Non-stimulant treatment for attention deficit hyperactivity disorder. Psychiatry (Edgmont). 2005;2(7):44–8.

    Google Scholar 

  5. Pozzi M, Carnovale C, Peeters GGAM, et al. Adverse drug events related to mood and emotion in paediatric patients treated for ADHD: a meta-analysis. J Affect Disord. 2018;238:161–78.

    Article  Google Scholar 

  6. Faraone SV, Schachar RJ, Barkley RA, et al. Early morning functional impairments in stimulant-treated children with attention-deficit/hyperactivity disorder versus controls: impact on the family. J Child Adolesc Psychopharmacol. 2017;27(8):715–22.

    Article  CAS  Google Scholar 

  7. Kollins SH. Abuse liability of medications used to treat attention-deficit/hyperactivity disorder (ADHD). Am J Addict. 2007;16(Suppl 1):35–42 (quiz 43-4).

    Article  Google Scholar 

  8. Faraone SV, Glatt SJ. A comparison of the efficacy of medications for adult attention-deficit/hyperactivity disorder using meta-analysis of effect sizes. J Clin Psychiatry. 2010;71(6):754–63.

    Article  Google Scholar 

  9. Padilha SCOS, Virtuoso S, Tonin FS, Borba HHL, Pontarolo R. Efficacy and safety of drugs for attention deficit hyperactivity disorder in children and adolescents: a network meta-analysis. Eur Child Adolesc Psychiatry. 2018;27(10):1335–45.

    Article  Google Scholar 

  10. Garnock-Jones KP, Keating GM. Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents. Paediatr Drugs. 2009;11(3):203–26.

    Article  Google Scholar 

  11. Lamb YN. Viloxazine: pediatric first approval. Pediatr Drugs. 2021;23(4):403–9.

    Article  Google Scholar 

  12. Viloxazine FDA prescribing information [cited 4 Oct 2021]. https://www.fda.gov/media/148484/download.

  13. Arnsten AF. Fundamentals of attention-deficit/hyperactivity disorder: circuits and pathways. J Clin Psychiatry. 2006;67(Suppl 8):7–12.

    CAS  PubMed  Google Scholar 

  14. Danchev ND, Rozhanets VV, Zhmurenko LA, Glozman OM, Zagorevskiĭ VA. Povedencheskiĭ i radioprotektornyĭ analiz stereoizomerov viloksazina [Behavioral and radioreceptor analysis of viloxazine stereoisomers]. Biull Eksp Biol Med. 1984;97(5):576–8.

    Article  CAS  Google Scholar 

  15. Yu C, Garcia-Olivares J, Candler S, et al. New insights into the mechanism of action of viloxazine: serotonin and norepinephrine modulating properties. J Exp Pharmacol. 2020;12:285–300.

    Article  CAS  Google Scholar 

  16. Johnson JK, Liriano T, Saylor K, et al. A phase II double-blind, placebo-controlled, efficacy and safety study of SPN-812 (extended-release viloxazine) in children with ADHD. J Atten Disord. 2020;24(2):348–58.

    Article  Google Scholar 

  17. Nasser A, Liriano T, Adewole T, et al. a phase 3, placebo-controlled trial of once-daily viloxazine extended-release capsules in adolescents with attention-deficit/hyperactivity disorder. J Clin Psychopharmacol. 2021;41(4):370–80.

    Article  CAS  Google Scholar 

  18. Nasser A, Liriano T, Adewole T, et al. A phase III, randomized, placebo-controlled trial to assess the efficacy and safety of once-daily SPN-812 (viloxazine extended-release) in the treatment of attention-deficit/hyperactivity disorder in school-age children. Clin Ther. 2020;42(8):1452–66.

    Article  CAS  Google Scholar 

  19. Nasser A, Liriano T, Adewole T, et al. Once-daily SPN-812 200 and 400 mg in the treatment of ADHD in school-aged children: a phase III randomized, controlled trial. Clin Ther. 2021;43(4):684–700.

    Article  CAS  Google Scholar 

  20. Nasser A, Liriano T, Adewole T, et al. A phase 3 placebo-controlled trial of once-daily 400-mg and 600-mg SPN-812 (viloxazine extended-release) in adolescents with ADHD. Psychopharmacol Bull. 2021;51(2):43–64.

    PubMed  Google Scholar 

  21. Cortese S, Adamo N, Del Giovane C, et al. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. Lancet Psychiatry. 2018;5(9):727–38.

    Article  Google Scholar 

  22. Findling RL, Candler SA, Nasser AF, et al. Viloxazine in the management of CNS disorders: a historical overview and current status. CNS Drugs. 2021;35(6):643–53. https://doi.org/10.1007/s40263-021-00825-w.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Faraone SV, Newcorn JH, Cipriani A, et al. Placebo and nocebo responses in randomised, controlled trials of medications for ADHD: a systematic review and meta-analysis. Mol Psychiatry. 2021. https://doi.org/10.1038/s41380-021-01134-w.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pharmacology, All India Institute of Medical Sciences, Raipur, Chhattisgarh, India

    Mahesh Kumar Balasundaram & Alok Singh

Authors
  1. Mahesh Kumar Balasundaram
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alok Singh
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alok Singh.

Ethics declarations

Funding

No sources of funding were used to assist in the preparation of this article.

Conflicts of interest

Mahesh Kumar Balasundaram and Alok Singh have no conflicts of interest to declare.

Ethical approval

Not applicable.

Consent to participate

Not applicable.

Consent for publication

Not applicable.

Availability of data and materials

Not applicable.

Code availability

Not applicable.

Author contributions

All authors contributed equally to this work.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Balasundaram, M.K., Singh, A. Viloxazine for attention-deficit hyperactivity disorder: a new formulation for a new indication. Drugs Ther Perspect 38, 77–83 (2022). https://doi.org/10.1007/s40267-022-00892-z

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40267-022-00892-z

Search

Navigation